Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 1/2011

01-01-2011 | Review

Induced pluripotent cancer cells: progress and application

Authors: Chun Sun, Yin Kun Liu

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2011

Login to get access

Abstract

Induced pluripotent stem (iPS) cells are a group of pluripotent stem cells artificially derived from non-pluripotent cells typically by a forced expression of specific transcription factors. Generation of cancer-specific iPS cells, also called induced pluripotent cancer (iPC) cells, provides valuable experimental platform to model oncogenesis and holds great potential in the fields of drug screening. However, iPC cells are harder to achieve than normal iPS cells probably because of the special genetic and epigenetic states of cancer cells. To help overcome this hurdle of iPC research and to prospect this promising field, this review emphasizes the experimental issues of reprogramming cancer into iPC cells, and discusses the potential of iPC cells in cancer research.
Literature
Atlasi Y, Mowla SJ, Ziaee SA, Bahrami AR (2007) OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer 120(7):1598–1602CrossRefPubMed
Bae KM, Su Z, Frye C, McClellan S, Allan RW, Andrejewski JT, Kelley V, Jorgensen M, Steindler DA, Vieweg J, Siemann DW (2010) Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol 183(5):2045–2053CrossRefPubMed
Blelloch RH, Hochedlinger K, Yamada Y, Brennan C, Kim M, Mintz B, Chin L, Jaenisch R (2004) Nuclear cloning of embryonal carcinoma cells. Proc Natl Acad Sci USA 101(39):13985–13990PubMed
Boltze C, Zack S, Quednow C, Bettge S, Roessner A, Schneider-Stock R (2003) Hypermethylation of the CDKN2/p16INK4A promotor in thyroid carcinogenesis. Pathol ResPract 199(6):399–404CrossRef
Bomken S, Fiser K, Heidenreich O, Vormoor J (2010) Understanding the cancer stem cell. Brit J cancer 103(4):439–445CrossRefPubMed
Carette JE, Pruszak J, Varadarajan M, Blomen VA, Gokhale S, Camargo FD, Wernig M, Jaenisch R, Brummelkamp TR (2010) Generation of iPSCs from cultured human malignant cells. Blood 115(20):4039–4042PubMed
Chang G, Miao YL, Zhang Y, Liu S, Kou Z, Ding J, Chen DY, Sun QY, Gao S (2010) Linking incomplete reprogramming to the improved pluripotency of murine embryonal carcinoma cell-derived pluripotent stem cells. PLoS One 5(4):e10320CrossRefPubMed
Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R (1998) DNA hypomethylation leads to elevated mutation rates. Nature 395(6697):89–93CrossRefPubMed
Eden A, Gaudet F, Waghmare A, Jaenisch R (2003) Chromosomal instability tumors promoted by DNA hypomethylation. Science 300(5618):455CrossRefPubMed
Eminli S, Foudi A, Stadtfeld M, Maherali N, Ahfeldt T, Mostoslavsky G, Hock H, Hochedlinger K (2009) Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet 41(9):968–976CrossRefPubMed
Feinberg AP (1999) Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction. Cancer Res 59(7 Suppl):1743s–1746sPubMed
Feinberg AP, Vogelstein B (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301(5895):89–92CrossRefPubMed
Florl AR, Lower R, Schmitz-Drager BJ, Schulz WA (1999) DNA methylation and expression of LINE-1 and HERV-k provirus sequences in urothelial and renal cell carcinomas. Br J Cancer 80(9):1312–1321CrossRefPubMed
Foster KW, Frost AR, McKie-Bell P, Lin CY, Engler JA, Grizzle WE, Ruppert JM (2000) Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Cancer Res 60(22):6488–6495PubMed
Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK, Frost AR, Louro ID, Townes TM, Paterson AJ, Kudlow JE, Lobo-Ruppert SM, Ruppert JM (2005) Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia. Oncogene 24(9):1491–1500CrossRefPubMed
Gardner L, Lee L, Dang C (2002) The c-Myc oncogenic transcription factor. In: The encyclopedia of cancer, 2nd edn. Academic Press
Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Gray JW, Leonhardt H, Jaenisch R (2003) Induction of tumors in mice by genomic hypomethylation. Science 300(5618):489–492CrossRefPubMed
Hanna J, Saha K, Pando B, van Zon J, Lengner CJ, Creyghton MP, van Oudenaarden A, Jaenisch R (2009) Direct cell reprogramming is a stochastic process amenable to acceleration. Nature 462(7273):595–601CrossRefPubMed
Hart AH, Hartley L, Parker K, Ibrahim M, Looijenga LH, Pauchnik M, Chow CW, Robb L (2005) The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. Cancer 104(10):2092–2098CrossRefPubMed
Henderson YC, Chen Y, Frederick MJ, Lai SY, Clayman GL (2010) MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther 9(7):1968–1976CrossRefPubMed
Hoei-Hansen CE, Almstrup K, Nielsen JE, Brask Sonne S, Graem N, Skakkebaek NE, Leffers H, Rajpert-De Meyts E (2005) Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours. Histopathology 47(1):48–56CrossRefPubMed
Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S (2009) Suppression of induced pluripotent stem cell generation by the p53–p21 pathway. Nature 460(7259):1132–1135CrossRefPubMed
Hu T, Liu S, Breiter DR, Wang F, Tang Y, Sun S (2008) Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res 68(16):6533–6540CrossRefPubMed
Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, Melton DA (2008a) Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 26(7):795–797CrossRefPubMed
Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S, Muhlestein W, Melton DA (2008b) Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 26(11):1269–1275CrossRefPubMed
Irish JM, Kotecha N, Nolan GP (2006) Mapping normal and cancer cell signalling networks towards single-cell proteomics. Nat Rev Cancer 6(2):146–155CrossRefPubMed
Judson RL, Babiarz JE, Venere M, Blelloch R (2009) Embryonic stem cell specific microRNAs promote induced pluripotency. Nat Biotechnol 27(5):459–461CrossRefPubMed
Li H, Collado M, Villasante A, Strati K, Ortega S, Cañamero M, Blasco MA, Serrano M (2009a) The ink/arf locus is a barrier for ips cell reprogramming. Nature 460(7259):1136–1139
Li W, Wei W, Zhu S, Zhu J, Shi Y, Lin T, Hao E, Hayek A, Deng H, Ding S (2009b) Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 4(1):16–19CrossRefPubMed
Lian Q, Zhang Y, Zhang J, Zhang HK, Wu X, Zhang Y, Lam FF, Kang S, Xia JC, Lai WH, Au KW, Chow YY, Siu CW, Lee CN, Tse HF (2010) Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation 121(9):1113–1123CrossRefPubMed
Lin SL, Chang DC, Chang-Lin S, Lin CH, Wu DT, Chen DT, Ying SY (2008) Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. RNA 14(10):2115–2124CrossRefPubMed
Liu D, Xing M (2008) Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3 K and NF-kappaB pathways. Thyroid 18(8):853–864CrossRefPubMed
Mallanna SK, Rizzino A (2010) Emerging roles of microRNAs in the control of embryonic stem cells and the generation of iPS cells. Dev Biol 344(1):16–25CrossRefPubMed
Marson A, Foreman R, Chevalier B, Bilodeau S, Kahn M, Young RA, Jaenisch R (2008) Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell Stem Cell 3(2):132–135CrossRefPubMed
Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D (1995) 5′CpG island methylation is associated with transcription silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1(7):686–692CrossRefPubMed
Mikkelsen TS, Hanna J, Zhang X, Ku M, Wernig M, Schorderet P, Bernstein BE, Jaenisch R, Lander ES, Meissner A (2008) Dissecting direct reprogramming through integrative genomic analysis. Nature 454(7200):49–55CrossRefPubMed
Mimeault M, Batra SK (2008) Recent progress on tissue-resident adult stem cell biology and their therapeutic implications. Stem Cell Rev 4(1):27–49CrossRefPubMed
Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, Tanaka F, Nagano H, Sekimoto M, Doki Y, Mori M (2010) Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci U S A 107(1):40–45CrossRefPubMed
Nagai K, Ishii H, Miyoshi N, Hoshino H, Saito T, Sato T, Tomimaru Y, Kobayashi S, Nagano H, Sekimoto M, Doki Y, Mori M (2010) Long-term culture following ES-like gene-induced reprogramming elicits an aggressive phenotype in mutated cholangiocellular carcinoma cells. Biochem Biophys Res Commun 395(2):258–263CrossRefPubMed
Nishii T, Yashiro M, Shinto O, Sawada T, Ohira M, Hirakawa K (2009) Cancer stem cell-like SP cells have a high adhesion ability to the peritoneum in gastric carcinoma. Cancer Sci 100(8):1397–1402CrossRefPubMed
Phi JH, Park SH, Kim SK, Paek SH, Kim JH, Lee YJ, Cho BK, Park CK, Lee DH, Wang KC (2008) Sox2 expression in brain tumors: a reflection of the neuroglial differentiation pathway. Am J Surg Pathol 32(1):103–112CrossRefPubMed
Raya A, Rodríguez-Pizà I, Guenechea G, Vassena R, Navarro S, Barrero MJ, Consiglio A, Castellà M, Río P, Sleep E, González F, Tiscornia G, Garreta E, Aasen T, Veiga A, Verma IM, Surrallés J, Bueren J, Izpisúa Belmonte JC (2009) Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 460(7251):53–59CrossRefPubMed
Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105–111CrossRefPubMed
Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, Rodriguez-Gil Y, Martinez MA, Hernandez L, Hardisson D, Reis-Filho JS, Palacios J (2007) Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 20(4):474–481CrossRefPubMed
Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K, Tsutani Y (2006) Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas 32(2):164–170CrossRefPubMed
Santagata S, Hornick JL, Ligon KL (2006) Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. Am J Surg Pathol 30(12):1613–1618CrossRefPubMed
Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Dammann R (2002) Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res 62(12):3698–3701PubMed
Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B (2009) Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun 383(2):157–162CrossRefPubMed
Shi Y, Do JT, Desponts C, Hahm HS, Schöler HR, Ding S (2008a) A combined chemical and genetic approach for the generation of induced pluripotent stem cells. Cell Stem Cell 2(6):525–528CrossRefPubMed
Shi Y, Desponts C, Do JT, Hahm HS, Schöler HR, Ding S (2008b) Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and klf with small-molecular compounds. Cell Stem Cell 3(5):568–574CrossRefPubMed
Silva J, Barrandon O, Nichols J, Kawaguchi J, Theunissen TW, Smith A (2008) Promotion of reprogramming to ground state pluripotency by signal inhibition. PLoS Biol 6(10):e253CrossRefPubMed
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663–676CrossRefPubMed
Tsou JA, Hagen JA, Carpenter CL, Laird-Offringa IA (2002) DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene 21(35):5450–5461CrossRefPubMed
Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, Khalil A, Rheinwald JG, Hochedlinger K (2009a) Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 460(7259):1145–1148CrossRefPubMed
Utikal J, Maherali N, Kulalert W, Hochedlinger K (2009b) Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci 122(Pt 19):3502–3510CrossRefPubMed
Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L (2008) Brca1 breast tumors contain distinct CD44+/CD24− and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 10(1):R10CrossRefPubMed
Xing M, Cohen Y, Mambo E, Tallini G, Udelsman R, Ladenson PW, Sidransky D (2004) Early ocurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res 64(5):1664–1668CrossRefPubMed
Yamanaka S (2009) Elite and stochastic models for induced pluripotent stem cell generation. Nature 460(7251):49–52CrossRefPubMed
Ye F, Zhou C, Cheng Q, Shen J, Chen H (2008) Stem-cell-abundant proteins nanog, nucleostemin and musashi1 are highly expressed in malignant cervical epithelial cells. BMC Cancer 8:108CrossRefPubMed
Zhao XY, Li W, Lv Z, Liu L, Tong M, Hai T, Hao J, Guo CL, Ma QW, Wang L, Zeng F, Zhou Q (2009) iPS cells produce viable mice through tetraploid complementation. Nature 461(7260):86–90CrossRefPubMed
Metadata
Title
Induced pluripotent cancer cells: progress and application
Authors
Chun Sun
Yin Kun Liu
Publication date
01-01-2011
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 1/2011
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0955-z

Other articles of this Issue 1/2011

Journal of Cancer Research and Clinical Oncology 1/2011 Go to the issue

Original Paper

Peroxisome-proliferator-activated receptors γ and β/δ mediate vascular endothelial growth factor production in colorectal tumor cells

Original Paper

Second primary esophageal or lung cancer in patients with head and neck carcinoma in Taiwan: incidence and risk in relation to primary index tumor site

Original Paper

Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model

Original Paper

Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib

Original Paper

Combined analysis of HPV DNA, p16, p21 and p53 to predict prognosis in patients with stage IV hypopharyngeal carcinoma

Original Paper

Circulating levels of angiogenic cytokines in advanced breast cancer patients with system chemotherapy and their potential value in monitoring disease course
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits